This Muscular Dystrophy Patient has Spent Her Life Working to Improve the Lives of Others
source: pixabay.com

This Muscular Dystrophy Patient has Spent Her Life Working to Improve the Lives of Others

Jalee Pelissier lives with muscular dystrophy. When she was just 13 she became an advocate for others with disorders or disabilities like her own. Now 20, her advocacy has only…

Continue Reading This Muscular Dystrophy Patient has Spent Her Life Working to Improve the Lives of Others
ICYMI Fulcrum Therapeutic’s Sickle Cell Disease Treatment On Track for a New Drug Application
source: pixabay.com

ICYMI Fulcrum Therapeutic’s Sickle Cell Disease Treatment On Track for a New Drug Application

As reported in Biospace, Fulcrum Therapeutics has announced it will be submitting an application to the FDA for FTX-6058 as an Investigational New Drug (IND) by the end of 2020…

Continue Reading ICYMI Fulcrum Therapeutic’s Sickle Cell Disease Treatment On Track for a New Drug Application
Study Discovers New Method to Predict Duchenne Muscular Dystrophy Progression
source: pixabay.com

Study Discovers New Method to Predict Duchenne Muscular Dystrophy Progression

According to a study published in the journal Neurology, a measure called the vastus lateralis fat fraction was found to be useful in predicting the age at which a patient living…

Continue Reading Study Discovers New Method to Predict Duchenne Muscular Dystrophy Progression
Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment
source: pixabay.com

Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment

According to a story from gurufocus.com, the biotechnology company Capricor Therapeutics has recently announced the initiation of a compassionate use program for its experimental drug CAP-1002. This drug will be…

Continue Reading Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment
CRISPR as a Tool to Treat Facioscapulohumeral Muscular Dystrophy
qimono / Pixabay

CRISPR as a Tool to Treat Facioscapulohumeral Muscular Dystrophy

  According to a press release from the Boston Children's Hospital, a study has discovered the efficacy of CRISPR-Cas9 gene-editing technology in the treatment of facioscapulohumeral muscular dystrophy (FSHD). As…

Continue Reading CRISPR as a Tool to Treat Facioscapulohumeral Muscular Dystrophy

This Journal Highlights Current Research on Neuromuscular Diseases (NMD)

In a Special Issue of the journal Disease Models and Mechanisms Highlights, James J. Dowling et al describes pediatric neuromuscular diseases as mostly genetic and affecting areas of the peripheral…

Continue Reading This Journal Highlights Current Research on Neuromuscular Diseases (NMD)
It Just Makes “Antisense:” Using Genetic Medicine to Treat Rare Diseases
source: pixabay.com

It Just Makes “Antisense:” Using Genetic Medicine to Treat Rare Diseases

  As previously published in Scientific American, slightly after her first birthday, Emma Larson lost the use of her legs and started experiencing difficulty crawling. She was diagnosed with spinal muscular…

Continue Reading It Just Makes “Antisense:” Using Genetic Medicine to Treat Rare Diseases
Mom of Seven Year Old with Duchenne Muscular Dystrophy Speaks at Recent Festival of Genomics
source: pixabay.com

Mom of Seven Year Old with Duchenne Muscular Dystrophy Speaks at Recent Festival of Genomics

  Shelley Simmonds recently attended the Festival of Genomics, the largest genomics event in the United Kingdom that is quickly growing into the biggest event in the world. It involves…

Continue Reading Mom of Seven Year Old with Duchenne Muscular Dystrophy Speaks at Recent Festival of Genomics
AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
source: pixabay.com

AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials

AskBio Asklepios BioPharmaceuticals (AskBio) was first founded in 2001. It is based out of North Carolina.  This company is dedicated to the research of gene therapies as potential therapeutic options…

Continue Reading AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases
source: pixabay.com

The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases

According to a story from Charcot-Marie-Tooth News, the Muscular Dystrophy Association (MDA) may at first seem like a group that is solely focused on helping muscular dystrophy patients, but its…

Continue Reading The Muscular Dystrophy Association Steps up for Rare Neuromuscular Diseases
Losmapimod Receives Orphan Drug Designation for the Treatment of FSHD
source: pixabay.com

Losmapimod Receives Orphan Drug Designation for the Treatment of FSHD

Losmapimod is an experimental treatment for facioscapulohumeral muscular dystrophy (FSHD), and it recently received the Orphan Drug designation from the FDA. Not only did it receive this designation, but its…

Continue Reading Losmapimod Receives Orphan Drug Designation for the Treatment of FSHD

With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two…

Continue Reading With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus
Translarna Results in a Preserved Ability to Walk in Those with Duchenne Muscular Dystrophy
Fotorech / Pixabay

Translarna Results in a Preserved Ability to Walk in Those with Duchenne Muscular Dystrophy

PTC Therapeutics is a pharmaceutical company that has been working with Translarna, a medication intended for the treatment of Duchenne muscular dystrophy (DMD). They analyzed this treatment and presented the…

Continue Reading Translarna Results in a Preserved Ability to Walk in Those with Duchenne Muscular Dystrophy
As the ACA Faces Another Court Challenge, Patient Groups Urge Quick Action
source: pixabay.com

As the ACA Faces Another Court Challenge, Patient Groups Urge Quick Action

According to a story from newsroom.heart.org, one of the most substantial domestic policy achievements of the Obama administration was the passage of the Affordable Care Act (ACA). Since its passage,…

Continue Reading As the ACA Faces Another Court Challenge, Patient Groups Urge Quick Action
The Muscular Dystrophy Association Awards Over $1M Towards Friedreich’s Ataxia Gene Therapy
source: pixabay.com

The Muscular Dystrophy Association Awards Over $1M Towards Friedreich’s Ataxia Gene Therapy

According to an announcement from the Muscular Dystrophy Association, the organization has recently awarded a total of $1,076,232 in MDA Venture Philanthropy (MVP) funding towards the drug company AavantiBio, which…

Continue Reading The Muscular Dystrophy Association Awards Over $1M Towards Friedreich’s Ataxia Gene Therapy
Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval
source: pixabay.com

Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval

According to a story from BioSpace, the US Food and Drug Administration (FDA) has recently approved the drug golodirsen (marketed as Vyondys 53) as a treatment for Duchenne muscular dystrophy…

Continue Reading Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval
A New Pediatric Precision Medicine Center is Opening in Utah
source: pixabay.com

A New Pediatric Precision Medicine Center is Opening in Utah

A new precision medicine center, specifically for pediatrics, has launched in Utah. This new center is the result of collaborative efforts from the Intermountain Primary Children's Hospital, Intermountain Precision Genomics,…

Continue Reading A New Pediatric Precision Medicine Center is Opening in Utah
Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA
source: pixabay.com

Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA

According to a story from tradeshownews.vporoom.com, the Muscular Dystrophy Association (MDA) has recently announced the official approval of its Patient-Focused Drug Development (PFDD) meeting by the US Food and Drug…

Continue Reading Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA
Two Nonprofits Award $200,000 Grant for Development of Duchenne Muscular Dystrophy Patient Reported Outcomes
source: pixabay.com

Two Nonprofits Award $200,000 Grant for Development of Duchenne Muscular Dystrophy Patient Reported Outcomes

According to a story from PR Newswire, the nonprofit groups Duchenne UK and Parent Project Muscular Dystrophy (PPMD) have jointly awarded grant funding to the tune of $200,000 to Dr.…

Continue Reading Two Nonprofits Award $200,000 Grant for Development of Duchenne Muscular Dystrophy Patient Reported Outcomes
Experimental Facioscapulohumeral Dystrophy Drug Found Safe and Tolerable in Phase 1 Study
jarmoluk / Pixabay

Experimental Facioscapulohumeral Dystrophy Drug Found Safe and Tolerable in Phase 1 Study

A recent press release from Fulcrum Therapeutics, a Massachusetts-based biotechnology company, announced preliminary findings of the company's phase 1 clinical study of losmapimod in the treatment of facioscapulohumeral dystrophy. Losmapimod is…

Continue Reading Experimental Facioscapulohumeral Dystrophy Drug Found Safe and Tolerable in Phase 1 Study
Study Analyzes New Outcome Measure for Duchenne Muscular Dystrophy
luvqs / Pixabay

Study Analyzes New Outcome Measure for Duchenne Muscular Dystrophy

According to a story from BioSpace, a global collaborative called the Trajectory Analysis Project recently released a study that utilized the North Star Ambulatory Assessment (NSAA), a recently developed measurement…

Continue Reading Study Analyzes New Outcome Measure for Duchenne Muscular Dystrophy